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Abstract: An isocratic, reversed phase-HPLC method was developed and validated for the quantitative
determination of Metformin and Linagliptin in combined dosage form. An Agilent Zorbax SB C18
(250mmx 4.6mm, 5µm) column with mobile phase containing KH2PO4: Acetonitrile (400:600) was used.
The flow rate was 1.0 mL/min, column temperature was 30°C and effluents were monitored at 236 nm.
The retention times of Metformin and Linagliptin were 1.532min and 2.071min respectively. The
correlation coefficient for Metformin and Linagliptin were found to be 0.99 and 0.99 respectively. The
proposed method was validated with respect to linearity, accuracy, precision, specificity, and robustness.
Recovery of Metformin and Linagliptin in formulations was found to be 100% and 100%   respectively
confirms the non-interferences of the excipients in the formulation. Due to its simplicity, rapidness and
high precision, this method was successfully applied to the estimation of Metformin and Linagliptin in
combined dosage form.
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I. INTRODUCTION
Metformin: It is an oral anti-diabetic drug in the
biguanide class. Metformin is chemically known as
N, N-Dimethylimidodicarbonimidicdiamide. It is
the first line drug of choice for the treatment of type
2 diabetes, particularly in overweight or obese
peoples and those with normal kidney function [1].
It is also used in the treatment of polycystic ovary
syndrome and has been investigated for other
diseases where insulin resistance may be an
important factor [2]. Metformin activates AMP-
activated protein kinase (AMPK), a liver enzyme
that plays an important role in insulin signaling,
whole body energy balance and metabolism of
glucose and fats. Activation of AMPK is required
for metformin’s inhibitory effect on the production
of glucose by liver cells [3].
Figure 1: Chemical structure of metformin
Linagliptin: Linagliptin is an oral drug that reduces
blood sugar (glucose) levels in patients with type 2
diabetes. Linagliptin is a member of a class of drugs
that inhibit the enzyme, dipeptidyl peptidase-4
(DPP-4) [4]. Other members of this class include
sitagliptin (Januvia), and saxagliptin (Onglyza).
Following a meal, increase in hormones such as
glucagon-like peptide-1(GLP-1), glucose-dependent
insulinotropic polypeptide (GIP) is released from
the intestine, and their levels increase in the blood.
GLP-1 and GIP reduce blood glucose by increasing
the production and release of insulin from the
pancreas. GLP-1 also reduces blood glucose by
reducing the secretion by the pancreas of the
hormone, glucagon, and a hormone that increases
the production of glucose by the liver and raises the
blood level of glucose. The net effect of increased
release of GLP-1 and GIP is to reduce blood
glucose levels. Linagliptin inhibits the enzyme,
DPP-4, that destroys GLP-1 and GIP and thereby
increases the levels and activity of both hormones.
As a result, levels of GLP-1 and GIP in the blood
remain higher, and blood glucose levels fall. In
summary, Linagliptin reduces blood glucose levels
by inhibiting DPP-4 and increasing the levels of
GLP-1 and GIP [5]. Linagliptin was approved by
the FDA in May 2011. Few analytical techniques
have been reported in the literature for the
simultaneous estimation of linagliptin and
metformin [6-9]. The present paper describes the
development of a simple, sensitive and rapid
stability indicating RP-HPLC method for the
simultaneous determination of metformin and
linagliptin.  The developed method was validated
according to ICH guidelines [10].
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Figure 2: Chemical structure of linagliptin
II. MATERIALS ANDMETHOD
A. Instrumentaion
The separation was carried out on HPLC system
with Waters 2695 alliance with binary HPLC pump,
Waters 2998 PDA detector, Waters Empower2
software and Agilent Zorbax SB C18 (250 mm x
4.6mm, 5µm).
B. Chemicals and Reagents
The working standards of metformin and linagliptin
were provided as gift samples from Lara drugs Pvt
Ltd., Hyderabad. Marketed formulation of
combination was purchased from local market.
Methanol of HPLC grade was purchased from E.
Merck (India) Ltd., Mumbai. KH2PO4: Acetonitrile(400:600) of AR grade were obtained from Sd Fine
Chemicals Ltd., Mumbai and milli Q water.
C. HPLC Conditions
The mobile phase consisting of 0.1M KH2PO4:Acetonitrile (HPLC grade) were filtered through
0.45µm membrane filter before use, degassed and
were pumped from the solvent reservoir in the ratio
of 400:600 v/v was pumped into the column at a
flow rate of 1.0 mL/min. The column temperature
was 30°C. The detection was monitored at 236 nm
and the run time was 10 min. The volume of
injection loop was 10 µL prior to injection of the
drug solution the column was equilibrated for at
least 30 min with the mobile phase flowing through
the system.
D. Preparation of standard solution
Metformin: Accurately weighed quantity 2000 mg
of metformin was transferred into 50 mL of
volumetric flask dissolve and diluted to volume
with mobile phase and sonicated for 15 min. From
the above solution 5 ml was taken into 25 ml
volumetric flask and make up the volume with
mobile phase.
Linagliptin: Accurately weighed quantity 10 mg of
linagliptin was transferred into 50ml of volumetric
flask dissolve and diluted to volume with mobile
phase and sonicated for 15 min. From the above
solution 5 ml was taken into 25ml volumetric flask
and make up the volume with mobile phase.
E. Preparation of sample solution
Take accurately sample powder equivalent to four
tablets and transfer it into 50ml of volumetric flask
dissolve and diluted to volume with mobile phase
and sonicated for 10 min. From the above solution
take 5 ml into 25ml volumetric flask make up the
volume with mobile phase.
F. Method validation
1. System Suitability Studies:
System suitability testing is an integral part of many
analytical procedures. The tests are based on the
concept that the equipment, electronics, analytical
operations and samples to be analyzed constitute an
integral system that can be evaluated as such.
System suitability test parameters to be established
for a particular procedure depend on the type of
procedure being validated.
TABLE I: SYSTEM SUITABILITY PARAMETERS
Parameters Metformin Linaglitpin
Retention
time
1.532 2.071
Resolution - 5.242
RSD 0.2 0.1
Theoretical
plates
4034 6202
Tailing 1.275 1.190
2. Specificity:
Specificity is the ability to assess unequivocally the
analyte in the presence of components which may
be expected to be present. Typically these might
include impurities, degradants, matrix, etc.
3. Accuracy and precision
The accuracy of an analytical procedure expresses
the closeness of agreement between the value which
is accepted either as a conventional true value or an
accepted reference value and the value found. The
accuracy of the method was determined by recovery
experiments. The recovery studies were carried out
at three concentration levels. Each level was
repeated six times. The percentage recovery and
standard deviation of the percentage recovery were
calculated. The mean recoveries of metformin and
linagliptin were found to be 100% and 100%. The
results indicated good accuracy of the method for
the determination of analyzed drugs as revealed by
mean recovery data (Table – II & III).
The precision of an analytical procedure expresses
the closeness of agreement (degree of scatter)
between a series of measurements obtained from
multiple sampling of the same homogeneous sample
under the prescribed conditions.
The precision of the method was demonstrated by
intra-day and inter-day variation studies. In the
intra-day studies the
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TABLE II: ACCURACY FORMETFORMIN
Spi
ked
Lev
el
Sam
ple
Wei
ght
Sam
ple
Area
µg/m
l
adde
d
µg/
ml
foun
d
%
reco
very
Me
an
50% 2110.00
1790
059
1982.
000
1973
.80 100 100
50% 2110.00
1796
644
1982.
000
1981
.07 100
50% 2110.00
1798
844
1982.
000
1983
.49 100
50% 2110.00
1798
222
1982.
000
1982
.81 100
50% 2110.00
1793
219
1982.
000
1977
.29 100
50% 2110.00
1798
521
1982.
000
1983
.13 100
100
%
4220
.00
3599
770
3964.
000
3969
.28 100 100
100
%
4220
.00
3593
767
3964.
000
3962
.66 100
100
%
4220
.00
3599
339
3964.
000
3968
.80 100
150
%
6330
.00
5391
794
5946.
000
5945
.25 100 100
150
%
6330
.00
5392
809
5946.
000
5946
.37 100
150
%
6330
.00
5397
451
5946.
000
5951
.49 100
150
%
6330
.00
5393
704
5946.
000
5947
.35 100
150
%
6330
.00
5397
186
5946.
000
5951
.19 100
150
%
6330
.00
5399
293
5946.
000
5953
.52 100
TABLE III: ACCURACY FOR LINAGLIPTIN
Spik
ed
Lev
el
Sam
ple
Wei
ght
Sam
ple
Area
µg/
ml
add
ed
µg/
ml
fou
nd
%
recov
ery
Me
an
50% 2110.00
2207
768
9.97
0
9.9
8 100
100
50% 2110.00
2201
353
9.97
0
9.9
5 100
50% 2110.00
2205
112
9.97
0
9.9
7 100
50% 2110 2205 9.97 9.9 100
.00 920 0 7
50% 2110.00
2205
509
9.97
0
9.9
7 100
50% 2110.00
2200
125
9.97
0
9.9
5 100
100
%
4220
.00
4412
268
19.9
40
19.
95 100
100
100
%
4220
.00
4411
638
19.9
40
19.
95 100
100
%
4220
.00
4414
954
19.9
40
19.
96 100
150
%
6330
.00
6613
824
29.9
10
29.
90 100
100
150
%
6330
.00
6615
195
29.9
10
29.
91 100
150
%
6330
.00
6612
080
29.9
10
29.
89 100
150
%
6330
.00
6611
441
29.9
10
29.
89 100
150
%
6330
.00
6611
059
29.9
10
29.
89 100
150
%
6330
.00
6617
984
29.9
10
29.
92 100
Figure 3: Accuracy chromatogram-50% of
metformin and linagliptin
Figure 4: Accuracy chromatogram-100% of
metformin and linagliptin
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Figure 5: Accuracy chromatogram-150% of
metformin and linagliptin
assay on six test preparations were performed by
injected into the chromatographic system as per the
test method. The % assay of drug and percentage
RSD were calculated. The inter-day variations of
the method also determined by using six replicate
injections of the same concentration and analyzed
on three consecutive days and response factor of
drugs peaks and percentage RSD were calculated.
The chromatograms of three different levels shown
in Figures 3, 4 & 5. From the data obtained, the
developed RP-HPLC method was found to be
precise (Table IV).
TABLE IV: PRECISION STUDIES
S.
No
Sam
ple
Wei
ght
Metfo
rmin
Linagl
iptin
%
Assay
(Metfo
rmin)
%
Assay
(Linagl
iptin)
1 4220.00
35969
60
44187
01 99 100
2 4220.00
35939
48
44137
71 99 100
3 4220.00
35996
73
44106
39 99 100
4 4220.00
35969
16
44128
84 99 100
5 4220.00
35994
39
44115
66 99 100
6 4220.00
35965
29
44107
10 99 100
Av
g.
As
say
99 100
ST
D 0.06 0.07
%
RS
D
0.06 0.07
4. Liniarity range:
The linearity of an analytical procedure is its ability
(within a given range) to obtain test results which
are directly proportional to the concentration
(amount) of analyte in the sample.  The range of an
analytical procedure is the interval between the
upper and lower concentration (amounts) of analyte
in the sample (including these concentrations) for
which it has been demonstrated that the analytical
procedure has a suitable level of precision, accuracy
and linearity.
Chromatographic method was tested for linearity by
plotting peak area against concentration of
solutions. The plot of peak area versus the
respective concentrations of metformin and
linagliptin were found to be linear in the
concentration range of 1000-3000 µg/mL and 5-15
µg/mL respectively. The regression equation for
metformin is y = 16616 x with a coefficient of
correlation (R2) of 0.99. The regression equation for
linagliptin is y = 19288 x with a coefficient of
correlation (R2) of 0.99.The results shows that an
excellent correlation exists between areas and
concentration of drugs within the concentration
range indicated above. And the results for
calibration curves are given in Figures 6 and 7.
5. Limit of detectin and limit of
quantification (LOD & LOQ):
The detection limit of an individual analytical
procedure is the lowest amount of analyte in a
sample which can be detected but not necessarily
quantitated as an exact value. The quantitation limit
of an individual analytical procedure is the lowest
amount of analyte in a sample which can be
quantitatively determined with suitable precision
and accuracy.
Figure 6: Linearity curve for metformin
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Figure 7: Linearity curve for linagliptin
The quantitation limit is a parameter of quantitative
assays for low levels of compounds in sample
matrices, and is used particularly for the
determination of impurities and/or degradation
products.
Limit of quantification and detection were predicted
by plotting linearity curves for different nominal
concentrations of Metformin, Linagliptin. Relative
standard deviation (σ) method was applied; the
LOQ and LOD values were predicted by using the
following formulas (a) and (b). Precision was
established at these predicted levels and the results
are tabulated in Table III & IV and chromatograms
were shown in Figures 8 and 9.
(a) LOQ = 10 σ / S
(b) LOD = 3.3 σ / S
Where σ = residual standard     deviation of
response; S = slope of the calibration curve.
Figure 8:  LOD chromatograms for metformin
and linagliptin
Figure 9:  LOQ chromatograms for metformin
and linagliptin
6. Robustness:
The robustness of an analytical procedure is a
measure of its capacity to remain unaffected by
small, but deliberate variations in method
parameters and provides an indication of its
reliability during normal usage. The Robustness of
the method was determined by making slight
changes in the chromatographic conditions. It was
observed that there were no marked changes in the
chromatograms, which demonstrated that the RP-
HPLC method developed is rugged and robust. The
results for robustness study are shown in Table V &
VI.
7. Forced degradation studies:
The stability studies were determined by applying
the physical stress (acid, base, peroxide, water and
light) to the product. It was observed that there were
marked degradation in the chromatograms, and the
data given in Tables VII & VIII and
chromatograms were shown in Figures 10-14.
TABLE V: ROBUSTNESS FORMETFORMIN
S
N
o
Sam
ple
nam
e
Injecti
on
RT Area Taili
ng
Plat
e
cou
nt
1 Flow
2
1ml 1.8
94
39506
23
1.271 616
1
2 Tem
p1
1ml 2.0
61
44309
15
1.288 614
9
3 Tem
p2
1ml 2.0
59
44045
54
1.295 645
5
4 Flow
1
1ml 2.2
89
49764
27
1.301 631
6
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TABLE VI: ROBUSTNESS FOR LINAGLIPTIN
S
N
o
Sam
ple
nam
e
Injecti
on
RT Area Taili
ng
Plat
e
cou
nt
1 Flow
2
1ml 1.5
25
36931
99
1.235 391
8
2 Tem
p1
1ml 1.3
92
33172
42
1.259 373
1
3 Tem
p2
1ml 1.5
32
35763
42
1.140 358
4
4 Flow
1
1ml 1.6
97
40308
03
1.255 384
0
TABLE VII: DEGRADATION STUDIES FOR
METFORMIN
Mode of
degradation
Condit
ions
Sam
ple
weig
ht
Area
%
Ass
ay
%
De
g.
Control
No
treatm
ent
- - - -
Acid
degradation
(5 N HCl)
40°C/5
min 4220
2969
960 82
-
17
Alkali
degradation
(1 N NaOH)
80°C/1
hr
4220 2673
941 74
-
25
Peroxidedeg
radation
(30%w/v
H2O2)
80°C/1
0 min
4220
2900
747 80
-
19
Light 200
watts
hrs/min
105°C/
72hr
4220 3209
979 88
-
11
Heat
105°C/72hr
25°C/7
2 hr
4220 3215
214 89
-
10
III. RESULTS ANDDISCUSSION
System suitability results were given by Table I and
system suitability parameters are retention time,
resolution, tailing and plate count were shown
uniformity and %RSD was less than 1(limit of
%RSD is less than 2.0%) so we can say that system
is suitable for the analysis. Method specificity was
concluded by standard chromatogram and
formulation chromatogram. There was no
interference from placebo and excipients peaks with
standard and analytic peaks. These results
demonstrate the absence of interference from other
materials. Hence it confirms the specificity of the
proposed method. The result given in Table IV says
that the method
TABLE VIII: DEGRADATION STUDIES FOR
LINAGLIPTIN
Mode of
degradation
Condit
ions
Sam
ple
weig
ht
Area
%
Ass
ay
%
De
g.
Control
No
treatm
ent
- - - -
Acid
degradation
(5 N HCl)
40°C/5
min 4220
3896
108 88
-
12
Alkali
degradation
(1 N NaOH)
80°C/1
hr
4220 3721
492 84
-
16
Peroxidedeg
radation
(30%w/v
H2O2)
80°C/1
0 min
4220
3928
421 89
-
11
Light 200
watts
hrs/min
105°C/
72hr
4220 4239
731 96 -4
Heat
105°C/72hr
25°C/7
2 hr
4220 4152
860 94 -6
Figure 10: Chromatogram of acid degradation
Figure 11: Chromatogram of acid  degradation
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Figure 12: Chromatogram of acid  degradation
Figure 13: Chromatogram of acid  degradation
Figure 14: Chromatogram of acid  degradation
precision passed for metformin and linagliptin
studies. The method accuracy was evaluated by
recovery studies. Metformin and linagliptin
recovery was founded 100% (as per ICH 97%-
103%) and also percentage RSD was very low so
method is accurate shown in Table II and III.
Linearity calibration curve was given above Figures
6 and 7 and plot the graph at different
concentrations versus areas to construct the linear
regression equation and to calculate the value of
correlation coefficient. Linear correlation was found
to be y = 16616 x for metformin, y = 119288 x for
linagliptin. The intra-day and inter-day variations
were calculated in terms of %RSD and results were
found to be intra-day and inter-day respectively.
Method robustness results were given by Table V
and VI.
IV. CONCLUSION
The proposed HPLC method was found to be
simple, precise, accurate and sensitive for the
simultaneous estimation of Metformin, Linagliptin
in pharmaceutical dosage forms. Hence, this method
can easily and conveniently adopt for routine
quality control analysis of Metformin, Linagliptin in
pure and its pharmaceutical dosage forms.
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